Boston Scientific Corp (NYSE:BSX) stock rose 1.61% (As on April 24, 11:24:13 AM UTC-4, Source: Google Finance) after the company reported first-quarter earnings and revenue that surpassed analyst expectations. Regionally, on an operational basis, the U.S. grew 31% with double-digit growth in 5 of our 8 business units. Midway through Q1, the company crossed the 1-year mark of the U.S. FARAPULSE launch and the 10-year anniversary of WATCHMAN’s approval, 2 clinically impactful technologies that have helped to transform the growth profile of Boston Scientific. Europe, Middle East and Africa grew 8% on an operational basis. This above-market growth was led by exceptional performance in EP as well as double-digit growth in the anchor technologies across the broader portfolio, including complex PCI, TheraSphere and Interventional Oncology, Axios and resume. Asia Pacific grew 11% operationally, led by double-digit growth in Japan. Japan is on track to have an excellent year led by strong FARAPULSE uptake. The company continues to anticipate launching FARAWAVE NAV and Fairview in the second half of the year. China also delivered high single-digit growth off a very tough 42% growth comp in first quarter ’24 and the company anticipates to deliver double-digit growth despite ongoing VBP pricing impacts in China.

Moreover, Urology sales grew 25% on an operational basis and 4% organically. Within DBS, the company saw improving growth exiting the quarter, driven by early contribution, the launch of the Cartesia leads and acceleration of the Illumina 3D programming algorithm in the U.S. Cardiology delivered another fantastic quarter with sales growing 31%.

BSX in the first quarter of FY25 has reported the adjusted earnings per share of 75 cents, beating the analysts’ estimates for the adjusted earnings per share of 67 cents. The company had reported the adjusted revenue growth of 20.9 percent to $4.66 billion in the first quarter of FY25, beating the analysts’ estimates for revenue of $4.57 billion. The topline grew 22.2 percent on an operational basis; and 18.2 percent on an organic basis, compared to the company’s guidance range of 14 to 16 percent, all compared to the prior year period.

The company raised its full-year 2025 adjusted EPS guidance to a range of $2.87 to $2.94 from $2.80-$2.87, also above the analyst consensus of $2.86. It expects organic revenue growth of 12% to 14% for the year.

For Q2 2025, Boston Scientific projects organic revenue growth of 13% to 15% and adjusted EPS to be between $0.71 and $0.73.